Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.

Michel Vulfovich1, Nabil Saba

  • 1Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Current Opinion in Molecular Therapeutics
|October 27, 2005
PubMed
Summary

Mapatumumab, a monoclonal antibody targeting tumor necrosis factor-related apoptosis-inducing ligand receptor 1, is being developed for cancer treatment. This therapy is currently in phase II clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions.

Head & neck·2026
Same author

Bispecific Antibodies in Solid Tumors: Advances and Challenges.

International journal of molecular sciences·2025
Same author

Claudins in Cancer: A Current and Future Therapeutic Target.

International journal of molecular sciences·2024
Same author

Folate Receptor Alpha-A Novel Approach to Cancer Therapy.

International journal of molecular sciences·2024
Same author

TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.

Oral oncology·2021
Same author

The role of the gut microbiome in cancer-related fatigue: pilot study on epigenetic mechanisms.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Mapatumumab is a human monoclonal antibody developed by Human Genome Sciences and GlaxoSmithKline.
  • It is licensed from Cambridge Antibody Technology.
  • Mapatumumab targets the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1).

Purpose of the Study:

  • To evaluate mapatumumab as a potential treatment for cancer.
  • To investigate the efficacy and safety of TRAIL-R1 agonists in oncology.

Main Methods:

  • Intravenous administration of mapatumumab.
  • Ongoing phase II clinical trials to assess therapeutic potential.
  • Development in Japan by Takeda.

Main Results:

Related Experiment Videos

  • Currently in phase II clinical trials, indicating preliminary positive progression.
  • Further results pending completion of clinical evaluations.

Conclusions:

  • Mapatumumab represents a promising targeted therapy for cancer.
  • Clinical trials are essential to confirm its therapeutic benefit in patients.